|本期目录/Table of Contents|

乳腺癌内分泌治疗加时代

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3713-3716
栏目:
综述
出版日期:
2019-09-08

文章信息/Info

Title:
Endocrine combined therapy of breast cancer
作者:
周 莉;?张百红
中国人民解放军联勤保障部队第九四〇医院肿瘤科,甘肃 兰州 730050
Author(s):
Zhou Li;?Zhang Baihong
Department of Oncology,No.940 Hospital of Joint Logistics Support Force of People's Liberation Army,Gansu Lanzhou 730050,China.
关键词:
乳腺肿瘤;?雌激素受体;?内分泌治疗
Keywords:
breast neoplasm;?estrogen receptors;?endocrine therapy
分类号:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.20.038
文献标识码:
A
qq自动领红包软件:
激素受体(HR)阳性乳腺癌对内分泌治疗有效但也会产生耐药,以内分泌治疗为基础的联合治疗克服了耐药并提高了内分泌治疗的效果。乳腺癌的治疗已进入内分泌治疗加时代,这包括乳腺癌内分泌治疗联合分子靶向药物、血管生成抑制剂、磷脂酰肌醇-3激酶(PI3K)抑制剂、哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂、细胞周期素依赖激酶(CDK)4/6抑制剂、抗HER2剂和表观遗传调节剂。本文系统总结乳腺癌内分泌联合治疗的临床研究结果和潜在药物。
Abstract:
Endocrine therapies that target the hormone receptors-positive breast cancer have substantial activity,yet the development of resistant to therapy is inevitable.The era of endocrine combined therapy of breast cancer has arrived.Combinational therapeutics can overcome resistance and improve clinical benefit.Combinational strategies include adding inhibitors targeting growth factors,angiogenesis,phosphoinositide 3-kinase (PI3K),mammalian target of rapamycin (mTOR),cyclin-dependent kinase 4/6,human epidermal growth factor receptor 2,or targeted epigenetic agents to endocrine therapy.Herein,we review the current study and new drugs of endocrine combined therapy of breast cancer.

参考文献/References

[1] Turner NC,Neven P,Loibl S,et al.Advances in the treatment of advanced oestrogen-receptor-positive breast cancer[J].Lancet,2017,389(10087):2403-2414.
[2] Vaz-Luis I,Partridge AH.Exogenous reproductive hormone use in breast cancer survivors and previvors[J].Nat Rev Clin Oncol,2018,15(4):249-261.
[3] Brufsky AM,Dickler MN.Estrogen receptor-positive breast cancer:Exploiting signaling pathways implicated in endocrine resistance[J].Oncologist,2018,23(5):528-539.
[4] Tryfonidis K,Basaran G,Bogaerts J,et al.A European Organisation for Research and Treatment of Cancer randomized,double-blind,placebo-controlled,multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378) [J].Eur J Cancer,2016(53):144-154.
[5] Zaman K,Winterhalder R,Mamot C,et al.Fulvestrant with or without selumetinib,a MEK 1/2 inhibitor,in breast cancer progressing after aromatase inhibitor therapy:A multicentre randomised placebo-controlled double-blind phase II trial,SAKK 21/08[J].Eur J Cancer,2015,51(10):1212-1220.
[6] Zhang Y,Wester L,He J,et al.IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer[J].Oncogene,2018,37(14):1869-1884.
[7] Robertson JF,Ferrero JM,Bourgeois H,et al.Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced,hormone-receptor-positive breast cancer:A randomised,controlled,double-blind,phase 2 trial[J].Lancet Oncol,2013,14(3):228-235.
[8] Qu X,Wu Z,Dong W,et al.Update of IGF-1 receptor inhibitor (ganitumab,dalotuzumab,cixutumumab,teprotumumab and figitumumab) effects on cancer therapy[J].Oncotarget,2017,8(17):29501-29518.
[9] Babina IS,Turner NC.Advances and challenges in targeting FGFR signalling in cancer[J].Nat Rev Cancer,2017,17(5):318-332.
[10] Martín M,Loibl S,von Minckwitz G,et al.Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer:The letrozole/fulvestrant and avastin (LEA) study[J].J Clin Oncol,2015,33(9):1045-1052.
[11] Dickler MN,Barry WT,Cirrincione CT,et al.Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer:CALGB 40503 (alliance) [J].J Clin Oncol,2016,34(22):2602-2609.
[12] Perez-Garcia J,Cortes J.Breast cancer in 2017:Spurring science,marking progress,and influencing history[J].Nat Rev Clin Oncol,2018,15(2):79-80.
[13] Finn RS,Martin M,Rugo HS,et al.Palbociclib and letrozole in advanced breast cancer[J].N Engl J Med,2016,375(20):1925-1936.
[14] Rugo HS,Diéras V,Gelmon KA,et al.Impact of palbociclib plus letrozole on patient reported health-related quality of life:Results from the PALOMA-2 trial[J].Ann Oncol,2018,29(4):888-894.
[15] Cristofanilli M,Turner NC,Bondarenko I,et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive,HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3):Final analysis of the multicentre,double-blind,phase 3 randomised controlled trial[J].Lancet Oncol,2016,17(4):425-439.
[16] Hortobagyi GN,Stemmer SM,Burris HA,et al.Ribociclib as first-line therapy for HR-positive,advanced breast cancer[J].N Engl J Med,2016,375(18):1738-1748.
[17] Sledge GW Jr,Toi M,Neven P,et al.MONARCH 2:Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy[J].J Clin Oncol,2017,35(25):2875-2884.
[18] Goetz MP,Toi M,Campone M,et al.MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol,2017,35(32):3638-3646.
[19] Pritchard KI,Chia SK,Simmons C,et al.Enhancing endocrine therapy combination strategies for the treatment of postmenopausal HR+/HER2-Advanced breast cancer[J].Oncologist,2017,22(1):12-24.
[20] Fruman DA,Chiu H,Hopkins BD,et al.The PI3K pathway in human disease[J].Cell,2017,170(4):605-635.
[21] Blenis J.TOR,the gateway to cellular metabolism,cell growth,and disease[J].Cell,2017,171(1):10-13.
[22] Pons-Tostivint E,Thibault B,Guillermet-Guibert J.Targeting PI3K signaling in combination cancer therapy[J].Trends Cancer,2017,3(6):454-469.
[23] Goldman KN,Chenette D,Arju R,et al.mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy[J].Proc Natl Acad Sci USA,2017,114(12):3186-3191.
[24] Baselga J,Im SA,Iwata H,et al.Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal,hormone receptor-positive,HER2-negative,advanced breast cancer (BELLE-2):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2017,18(7):904-916.
[25] Di Leo A,Johnston S,Lee KS,et al.Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive,HER2-negative,advanced breast cancer progressing on or after mTOR inhibition (BELLE-3):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2018,19(1):87-100.
[26] Krop IE,Mayer IA,Ganju V,et al.Pictilisib for oestrogen receptor-positive,aromatase inhibitor-resistant,advanced or metastatic breast cancer (FERGI):A randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet Oncol,2016,17(6):811-821.
[27] Juric D,Rodon J,Tabernero J,et al.Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors:Results from the first-in-human study[J].J Clin Oncol,2018,36(13):1291-1299.
[28] Mayer IA,Abramson VG,Formisano L,et al.A phase Ib study of alpelisib (BYL719),a PI3Kα-specific inhibitor,with letrozole in ER+/HER2-metastatic breast cancer[J].Clin Cancer Res,2017,23(1):26-34.
[29] Hortobagyi GN,Chen D,Piccart M,et al.Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:Results from BOLERO-2[J].J Clin Oncol,2016,34(5):419-426.
[30] Wolff AC,Lazar AA,Bondarenko I,et al.Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J].J Clin Oncol,2013,31(2):195-202.
[31] Ma CX,Sanchez C,Gao F,et al.A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer[J].Clin Cancer Res,2016,22(11):2650-2658.
[32] Prat A,Cheang MC,Galván P,et al.Prognostic value of intrinsic aubtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib[J].JAMA Oncol,2016,2(10):1287-1294.
[33] Dawson MA.The cancer epigenome:Concepts,challenges,and therapeutic opportunities[J].Science,2017,355(6330):1147-1152.
[34] Yeruva SLH,Zhao F,Miller KD,et al.E2112:Randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer[J].NPJ Breast Cancer,2018(4):1.
[35] Schiewer MJ,Knudsen KE.Not so fast:Cultivating miRs as kinks in the chain of the cell cycle[J].Cancer Cell,2017,31(4):471-473.
[36] Thompson ED,Taube JM,Asch-Kendrick RJ,et al.PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast[J].Mod Pathol,2017,30(11):1551-1560.
[37] Goedert JJ,Hua X,Bielecka A,et al.Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota[J].Br J Cancer,2018,118(4):471-479.
[38] Bhatt AP,Redinbo MR,Bultman SJ.The role of the microbiome in cancer development and therapy[J].CA Cancer J Clin,2017,67(4):326-344.
[39] Greenlee H,DuPont-Reyes MJ,Balneaves LG,et al.Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment[J].CA Cancer J Clin,2017,67(3):194-232.
[40] Demark-Wahnefried W,Schmitz KH,Alfano CM,et al.Weight management and physical activity throughout the cancer care continuum[J].CA Cancer J Clin,2018,68(1):64-89.

备注/Memo

备注/Memo:
甘肃省自然科学基金项目(编号:1308RJZA181)
更新日期/Last Update: 1900-01-01